CASI Pharmaceuticals Files 6-K
Ticker: CASIF · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals
TL;DR
CASI Pharma filed a 6-K on 6/27/24, standard foreign issuer report from Beijing.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on June 27, 2024, reporting information as a foreign private issuer. The filing indicates the company operates in the Pharmaceutical Preparations sector and is incorporated in E9 with a fiscal year end of December 31. The company's principal executive offices are located in Beijing, People's Republic of China.
Why It Matters
This filing provides routine updates for CASI Pharmaceuticals, Inc. as a foreign private issuer, which is important for investors tracking the company's regulatory disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- 001-41666 (company) — SEC File Number
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District Beijing, 100025 People's Republic of China (company) — Business Address
- CASI Pharmaceuticals Holdings, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is CASI Pharmaceuticals, Inc.'s Standard Industrial Classification (SIC) code?
CASI Pharmaceuticals, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was CASI Pharmaceuticals, Inc. formerly known as CASI Pharmaceuticals Holdings, Inc.?
The date of the name change from CASI Pharmaceuticals Holdings, Inc. to CASI Pharmaceuticals, Inc. was January 18, 2023.
Where are CASI Pharmaceuticals, Inc.'s principal executive offices located?
The company's principal executive offices are located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals, Inc. file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals, Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-06-27 07:26:41
Filing Documents
- tmb-20240627x6k.htm (6-K) — 18KB
- tmb-20240627xex99.htm (EX-99) — 20KB
- tmb-20240627xex99001.jpg (GRAPHIC) — 10KB
- 0001962738-24-000033.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: June 27, 2024